About QBiotics
QBiotics is a company based in Brisbane (Australia) founded in 2000 by Victoria Gordon and Paul Reddell. It operates as a HealthTech. QBiotics has raised $98.07 million across 3 funding rounds from investors including TDM Growth Partners. QBiotics offers products and services including Tigilanol Tiglate, EBC-1013, and STELFONTA. QBiotics operates in a competitive market with competitors including Jazz Pharmaceuticals, Zoetis, Ceva, C4 Therapeutics and Erasca, among others.
- Headquarter Brisbane, Australia
- Founders Victoria Gordon, Paul Reddell
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Qbiotics Group
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$98.07 M (USD)
in 3 rounds
-
Latest Funding Round
$64.42 M (USD), Series C
Jun 25, 2021
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of QBiotics
QBiotics offers a comprehensive portfolio of products and services, including Tigilanol Tiglate, EBC-1013, and STELFONTA.
Developed as treatment for soft tissue sarcomas oncology.
Designed for treatment of chronic and acute wounds.
Approved for non-resectable mast cell tumors in dogs.
Funding Insights of QBiotics
QBiotics has successfully raised a total of $98.07M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $64.42 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $64.4M
-
First Round
First Round
(01 Jun 2016)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Series C - QBiotics | Valuation | TDM Growth Partners |
|
| Feb, 2020 | Amount | Series B - QBiotics | Valuation |
investors |
|
| Jun, 2016 | Amount | Series B - QBiotics | Valuation |
investors |
|
Investors in QBiotics
QBiotics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include TDM Growth Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth capital is offered by TDM Growth Partners.
|
Founded Year | Domain | Location |
Investments & Acquisitions by QBiotics
Financial Statements - QBiotics
Qbiotics Comparisons
Competitors of QBiotics
QBiotics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Zoetis, Ceva, C4 Therapeutics and Erasca, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Animal medicines, vaccines, and diagnostics are manufactured and supplied.
|
|
| domain | founded_year | HQ Location |
Animal health therapeutics are developed and supplied globally by Ceva.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
Frequently Asked Questions about QBiotics
QBiotics was founded in 2000 and raised its 1st funding round 16 years after it was founded.
QBiotics is headquartered in Brisbane, Australia. It is registered at Brisbane, Queensland, Australia.
Victoria Gordon is the current CEO of QBiotics. They have also founded this company.
QBiotics is a funded company, having raised a total of $98.07M across 3 funding rounds to date. The company's 1st funding round was a Series B of $22.1M, raised on Jun 01, 2016.
QBiotics is engaged in the discovery and development of novel cell signaling small molecules for challenging medical conditions. The company operates in the healthcare sector, specializing in oncology and wound healing solutions. Its lead oncology drug, Tigilanol Tiglate, is in clinical Phase II trials for soft tissue sarcomas and head and neck cancers. Additionally, EBC-1013 is being developed for chronic and acute wounds, with a Phase I trial planned. Veterinary oncology product STELFONTA is commercialized for mast cell tumors in dogs. Innovation is driven by proprietary platforms like EcoLogic and phenotypic screening, leveraging Australias tropical rainforest molecular diversity.
QBiotics's top competitors include Jazz Pharmaceuticals, Zoetis and C4 Therapeutics.
QBiotics offers Tigilanol Tiglate, EBC-1013, and STELFONTA.
QBiotics has 1 investor. Key investors include TDM Growth Partners.